Portola Pharmaceuticals - Top 20 VC deals of 2007

Company: Portola Pharmaceuticals
Based: South San Francisco, CA
Amount: $70M
Round: Third
Investors: Abingworth Management. Advanced Technology Ventures, AllianceBernstein, Alta Partners, Brookside International Incorporated, CIDC Consultants, Frazier Healthcare and Technology Ventures, Goldman, Sachs & Co., MPM Capital, Ontario Teachers Pension Plan, Prospect Venture Partners, Sutter Hill Ventures, T. Rowe Price Threshold, Partnerships, Undisclosed Investor

Scoop: Portola's lead drug is PRT054021, a therapy for prevention and treatment of deep vein thrombosis and pulmonary embolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation, and for secondary prevention of myocardial infarction and stroke. In July Portola turned in positive PRT054021 Phase II data for patients undergoing knee replacement surgery. In addition to PRT054021, Portola has a Phase I drug--PRT060128--for acute coronary syndrome, the prevention of cardiovascular events in patients undergoing percutaneous coronary intervention and secondary prevention of MI and stroke. A Phase II trial of the drug is underway.

More News:
A race to the finish for blockbuster blood thinners. Report
Portola pockets $70M in third round. Report
Portola gains $20M. Report
Portola raises $46M. Report

Portola Pharmaceuticals - Top 20 VC deals of 2007
Read more on

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.